

Oxtellar XR[®] (oxcarbazepine) – First-time generic

- On September 1, 2024, [Apotex launched](#) an [AB-rated](#) generic version of Supernus' [Oxtellar XR \(oxcarbazepine\)](#) extended-release tablets.
- Oxtellar XR is approved for the treatment of partial-onset seizures in patients 6 years of age and older.
- Oxcarbazepine is also available generically as a [suspension](#) and a [tablet](#).
 - The oral suspension and tablet are approved for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.